The long-term goals ofthe Hematopoietic Development & Malignancy Program (HDMP) are to elucidate basic mechanisms regulating normal and malignant hematopoiesis and to use this information to develop strategies for the prevention, diagnosis, prognostic stratification, and treatment of hematopoietic malignancies. We have identified areas of institutional strength and developed the following specific translational goals of the HDMP: 1) to leverage local expertise in cancer genomics to identify novel recurrent mutations in hematopoietic malignancies and develop their translational potential; 2) to expand translational research in multiple myeloma and lymphoma; 3) to take advantage of local expertise in fundamental hematopoiesis research to expand translational research in bone marrow failure syndromes; 4) to utilize local expertise in fundamental immunology and stem cell biology research to expand translational research in stem cell transplantation. Working groups in leukemia, lymphoma & myeloma, bone marrow failure and transplantation biology have been established to develop, review, prioritize and conduct translational research. The HDMP will foster collaborative translational research and provide training of junior investigators through research seminars, journal clubs, work-in-progress meetings and the annual HDMP retreat. The HDMP has 29 members from four Departments and one School. The HDMP is supported by $11,684,316 in funding, of which $4,798,898 is NCI funding and $6,264,597 is other peer reviewed funding. In the last grant period, members ofthe HDMP published 260 manuscripts, of which 34.6% represent interprogrammatic and 13.1% resulted from intra-programmatic collaborations.

Public Health Relevance

The goal of the Hematopoietic Development &Malignancy Program is to improve the diagnosis and treatment of blood cancers, including leukemia, multiple myeloma, and lymphoma through clinical application of advances in basic research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA091842-11
Application #
8380291
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$62,816
Indirect Cost
$55,505
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Eberth, Jan M; Josey, Michele J; Mobley, Lee R et al. (2017) Who Performs Colonoscopy? Workforce Trends Over Space and Time. J Rural Health :
Kuroki, Lindsay M; Frolova, Antonina I; Wu, Ningying et al. (2017) Yield of Cytology Surveillance After High-Grade Vulvar Intraepithelial Neoplasia or Cancer. J Low Genit Tract Dis 21:193-197
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Cusworth, Brian M; Krasnick, Bradley A; Nywening, Timothy M et al. (2017) Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 19:147-153
Wang, Xuya; Mooradian, Arshag D; Erdmann-Gilmore, Petra et al. (2017) Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Sci Signal 10:
Knoop, Kathryn A; Gustafsson, Jenny K; McDonald, Keely G et al. (2017) Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. Sci Immunol 2:
Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105
Song, Hao; Ruan, Dan; Liu, Wenyang et al. (2017) Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. Med Phys 44:962-973
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Lim, Kian-Huat; Langley, Emma; Gao, Feng et al. (2017) A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget 8:24250-24261

Showing the most recent 10 out of 1109 publications